Camrelizumab plus chemotherapy as adjuvant treatment for node-positive stage IIICp cervical cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase 2 interventional trial of camrelizumab combined with chemotherapy given as adjuvant treatment after radical surgery for patients with pathologically confirmed lymph node–positive cervical cancer. Eligible participants must have FIGO2018 stage IIIC1p or IIIC2p disease, positive PD-L1 expression, and an ECOG score of 0–1. Patients with positive surgical margins, residual lesions, incomplete surgery, active autoimmune disease, or prior immune checkpoint inhibitor treatment are excluded. The study aims to measure the efficacy of the combination regimen in preventing recurrence compared with historical expectations for chemotherapy alone.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients with cervical cancer staged FIGO2018 IIIC1p or IIIC2p after radical surgery;
2. Positive PD-L1 expression;
3. ECOG score ≤1

Exclusion Criteria:

1. Positive parametrium or surgical margin;
2. Incomplete radical surgery;
3. Residual target lesions;
4. Active autoimmune disease or autoimmune disease requiring systemic treatment;
5. Previous treatment with immune checkpoint inhibitors.

Where it's running

• Women's Hospital, School of Medicine, Zhejiang University
  Hangzhou, Zhejiang, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Neoadjuvant immunochemotherapy for PD-L1-negative locally advanced cervical cancer

  This study is testing a new treatment that combines chemotherapy with a drug called Camrelizumab to see if it can help people with PD-L1-negative locally advanced cervical cancer before surgery.

  Recruiting at 12 sites Phase 2 Tongji Hospital · Hefei, Anhui and 11 other locations · NCT06288360

• Cervical screening and care options for women living with HIV who test positive for high-risk HPV

  This study tests different ways to screen and manage high-risk HPV in women with HIV to see what might work best for them.

  Recruiting University of California, San Diego · Nairobi · NCT07925307

• Hydrogel spacer to protect the rectum during cervical cancer radiotherapy

  This study tests whether placing an absorbable hydrogel spacer between the cervix/vagina and rectum before definitive radiotherapy can reduce rectal radiation exposure for women with cervical cancer.

  Recruiting Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07904182

• How cinema sessions during chemotherapy might help cervical cancer patients

  We’re testing if watching films during chemotherapy helps cervical cancer patients feel less anxious and improve quality of life.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Roma · NCT07902180

• Ivarmacitinib with Camrelizumab and Fruquintinib in advanced colorectal cancer after prior therapies

  This trial tests whether combining ivarmacitinib with camrelizumab and fruquintinib can help patients with metastatic colorectal cancer who have progressed after multiple treatments.

  Recruiting Phase 2 Renmin Hospital of Wuhan University · Wuhan, Hubei · NCT07896096

• One-Finger Technique to identify the left upper ureter during para-aortic lymphadenectomy

  This study tests a new surgical method to help surgeons find the left upper ureter during open para-aortic lymphadenectomy in women with gynecologic cancers.

  Recruiting Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07895212

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.